68-Gallium DOTATATE
2 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| 68-Gallium DOTATATE for neuroectodermal tumors, primitive | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 68-Gallium DOTATATE for neuroendocrine tumors | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |